Effectiveness of sotalol treatment in symptomatic Brugada syndrome

Am J Cardiol. 2004 May 15;93(10):1320-2. doi: 10.1016/j.amjcard.2004.02.023.


We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Arrhythmia Agents / therapeutic use*
  • Diagnosis, Differential
  • Electrocardiography
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Middle Aged
  • Pedigree
  • Sotalol / therapeutic use*
  • Syndrome
  • Ventricular Fibrillation / diagnosis*
  • Ventricular Fibrillation / drug therapy*
  • Ventricular Fibrillation / genetics
  • Ventricular Fibrillation / physiopathology


  • Anti-Arrhythmia Agents
  • Sotalol